{"id":"short-term-androgen-deprivation","safety":{"commonSideEffects":[{"rate":"50–80","effect":"Hot flashes"},{"rate":"40–70","effect":"Erectile dysfunction"},{"rate":"30–50","effect":"Fatigue"},{"rate":"40–60","effect":"Decreased libido"},{"rate":"10–20","effect":"Gynecomastia"},{"rate":null,"effect":"Bone density loss"},{"rate":null,"effect":"Metabolic syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ADT works by blocking the production or action of androgens (primarily testosterone), which are required for prostate cancer cell proliferation. Short-term ADT is typically administered for 4–6 months in combination with external beam radiation therapy or other treatments in intermediate- to high-risk prostate cancer. This approach aims to reduce tumor burden and improve treatment efficacy while minimizing long-term toxicity associated with prolonged hormone deprivation.","oneSentence":"Short-term androgen deprivation therapy (ADT) temporarily suppresses testosterone production to slow or stop the growth of androgen-dependent prostate cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:24.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intermediate- to high-risk localized prostate cancer (in combination with radiation therapy)"},{"name":"Locally advanced prostate cancer"}]},"trialDetails":[{"nctId":"NCT07483658","phase":"NA","title":"Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.","status":"NOT_YET_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2026-02","conditions":"Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy), Prostate Cancer","enrollment":434},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT06111313","phase":"PHASE2","title":"The University of Miami Adapt (UAdapt) Trial","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-11-06","conditions":"Prostate Cancer","enrollment":130},{"nctId":"NCT01517451","phase":"PHASE1, PHASE2","title":"Radiation and Androgen Ablation for Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-05-22","conditions":"Adenocarcinoma of the Prostate","enrollment":45},{"nctId":"NCT07202247","phase":"PHASE2","title":"Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-23","conditions":"Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":60},{"nctId":"NCT07364071","phase":"PHASE2","title":"Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-04","conditions":"Prostate Adenocarcinoma","enrollment":150},{"nctId":"NCT00579072","phase":"","title":"The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-08","conditions":"Prostate Cancer","enrollment":230},{"nctId":"NCT05746806","phase":"NA","title":"Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-29","conditions":"Recurrent Prostate Cancer","enrollment":36},{"nctId":"NCT05346848","phase":"PHASE2","title":"Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2023-02-24","conditions":"Prostate Cancer","enrollment":62},{"nctId":"NCT01436968","phase":"PHASE3","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":711},{"nctId":"NCT05191680","phase":"PHASE2","title":"TherApeutics in Early ProState Cancer (TAPS02)","status":"RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2023-04-24","conditions":"Prostate Cancer","enrollment":90},{"nctId":"NCT00567580","phase":"PHASE3","title":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":1792},{"nctId":"NCT04302454","phase":"PHASE3","title":"Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2020-03-19","conditions":"Prostate Cancer","enrollment":280},{"nctId":"NCT01985828","phase":"NA","title":"CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-11-19","conditions":"Prostate Adenocarcinoma","enrollment":83},{"nctId":"NCT05781217","phase":"PHASE3","title":"Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-03-14","conditions":"Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence","enrollment":534},{"nctId":"NCT03845751","phase":"PHASE2","title":"EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.","status":"UNKNOWN","sponsor":"Institut Mutualiste Montsouris","startDate":"2023-01","conditions":"Prostate Cancer, Androgen Deprivation Therapy","enrollment":20},{"nctId":"NCT01717053","phase":"PHASE2","title":"Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-01-17","conditions":"Prostate Cancer","enrollment":37},{"nctId":"NCT02295163","phase":"NA","title":"Stellate Ganglion Block for Hot Flushes in Men Treated With ADT","status":"WITHDRAWN","sponsor":"Rijnstate Hospital","startDate":"2014-07","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02175212","phase":"PHASE3","title":"Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2005-11","conditions":"Prostate Adenocarcinoma","enrollment":362},{"nctId":"NCT00702923","phase":"PHASE1","title":"CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2008-07","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT01811810","phase":"NA","title":"Proton Therapy for High Risk Prostate Cancer","status":"WITHDRAWN","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2013-03","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00006214","phase":"PHASE2","title":"Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-08","conditions":"Prostate Cancer","enrollment":63},{"nctId":"NCT01398657","phase":"PHASE3","title":"Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2011-07","conditions":"Prostate Cancer","enrollment":182},{"nctId":"NCT01006902","phase":"","title":"Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and Correlates of Change","status":"TERMINATED","sponsor":"University of Vermont","startDate":"2009-11","conditions":"Cancer","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":113,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neoadjuvant and concomitant"],"phase":"phase_3","status":"active","brandName":"Short term androgen deprivation","genericName":"Short term androgen deprivation","companyName":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","companyId":"fundaci-n-de-investigaci-n-biom-dica-hospital-universitario-de-la-princesa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Short-term androgen deprivation therapy (ADT) temporarily suppresses testosterone production to slow or stop the growth of androgen-dependent prostate cancer cells. Used for Intermediate- to high-risk localized prostate cancer (in combination with radiation therapy), Locally advanced prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}